Compare KTTA & MFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KTTA | MFC |
|---|---|---|
| Founded | 2020 | 1887 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 60.8B |
| IPO Year | 2021 | 1999 |
| Metric | KTTA | MFC |
|---|---|---|
| Price | $1.15 | $36.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $52.00 |
| AVG Volume (30 Days) | ★ 17.9M | 2.5M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | ★ 3.40% |
| EPS Growth | N/A | ★ 10.85 |
| EPS | N/A | ★ 2.24 |
| Revenue | N/A | ★ $22,912,074,891.00 |
| Revenue This Year | N/A | $34.60 |
| Revenue Next Year | N/A | $8.50 |
| P/E Ratio | ★ N/A | $16.38 |
| Revenue Growth | N/A | ★ 6.09 |
| 52 Week Low | $0.28 | $25.92 |
| 52 Week High | $3.85 | $36.86 |
| Indicator | KTTA | MFC |
|---|---|---|
| Relative Strength Index (RSI) | 59.44 | 70.83 |
| Support Level | $1.02 | $36.08 |
| Resistance Level | $1.21 | $35.61 |
| Average True Range (ATR) | 0.09 | 0.45 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 50.22 | 87.59 |
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
Manulife Financial is one of the Big Three Canadian life insurers. The firm provides life insurance, annuities, asset management, and wealth management products to individuals and group customers in Canada, the United States, and Asia. The Canadian business segment contributes approximately 22% of adjusted earnings. The Asia segment operates across 12 countries and contributes around 36% of earnings, with a significant presence in Hong Kong and Singapore. The US business, which primarily operates under the John Hancock brand, contributes about 23% of earnings. Manulife's global asset and wealth management business contributes approximately 20% of its earnings and had around CAD 1.03 trillion in assets under management and administration as of the end of 2024.